IGM Biosciences, Inc. (IGMS)
Market Cap | 868.43M |
Revenue (ttm) | 2.91M |
Net Income (ttm) | -220.40M |
Shares Out | 59.32M |
EPS (ttm) | -3.67 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 99,420 |
Open | 13.72 |
Previous Close | 13.72 |
Day's Range | 13.72 - 15.04 |
52-Week Range | 3.81 - 22.50 |
Beta | 0.21 |
Analysts | Hold |
Price Target | 14.00 (-4.37%) |
Earnings Date | Nov 11, 2024 |
About IGMS
IGM Biosciences, Inc., a clinical-stage biotechnology company, develops Immunoglobulin M (IgM) antibodies for the treatment of cancer and autoimmune and inflammatory diseases. It develops Aplitabart, a Death Receptor 5 Agonist IgM antibody for the treatment of colorectal cancer; imvotamab, a CD20 x CD3 bispecific IgM antibody to treat myositis, as well as for the treatment of systemic lupus erythematosus and rheumatoid arthritis that is Phase Ib clinical trial; and IGM-2644, a bispecific T cell engaging IgM antibody targeting CD38 and CD3 prote... [Read more]
Financial Performance
In 2023, IGM Biosciences's revenue was $2.13 million, an increase of 99.25% compared to the previous year's $1.07 million. Losses were -$246.42 million, 11.4% more than in 2022.
Financial StatementsAnalyst Forecast
According to 8 analysts, the average rating for IGMS stock is "Hold." The 12-month stock price forecast is $14.0, which is a decrease of -4.37% from the latest price.
News
IGM Biosciences' stock tumbles as analysts weigh in on pivot plan with dismay
IGM Biosciences Inc.'s stock tumbled 14% Tuesday, as analysts weighed in with dismay on the company's pivot away from oncology to a focus on autoimmune diseases, with at least two opting to lower thei...
IGM Biosciences' New Found Focus: Pivots From Cancer To Autoimmune Diseases, Names New CEO
On Tuesday, IGM Biosciences Inc. IGMS announced a strategic pivot and pipeline transformation to accelerate and deepen its leadership in developing T cell-engaging IgM antibodies for autoimmune diseas...
IGM Biosciences Stock Drops 27% on ‘Pipeline Transformation' to Autoimmune Diseases
The biotechnology company says it will focus only on autoimmune diseases.
IGM Biosciences, CPI Card And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
U.S. stock futures were mixed this morning, with the Dow futures falling around 100 points on Tuesday.
IGM Biosciences Announces Strategic Pivot to Focus Exclusively on Autoimmunity
– Company to prioritize its pipeline of T cell engagers in autoimmune diseases, including ongoing clinical development of imvotamab in rheumatoid arthritis and systemic lupus erythematosus –
IGM Biosciences to Present at the Stifel 2024 Virtual Immunology and Inflammation Summit
MOUNTAIN VIEW, Calif., Sept. 10, 2024 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company creating and developing engineered IgM antibodies, today announce...
IGM Biosciences Announces Second Quarter 2024 Financial Results and Provides Corporate Update
– Enrollment complete in aplitabart randomized colorectal cancer clinical trial; top-line PFS results expected by the end of 1Q25 –
IGM Biosciences to Present at the Jefferies Healthcare Conference
MOUNTAIN VIEW, Calif., May 29, 2024 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company creating and developing engineered IgM antibodies, today announced ...
IGM Biosciences Announces First Quarter 2024 Financial Results and Provides Corporate Update
- Enrollment target exceeded in aplitabart randomized colorectal cancer clinical trial - - Enrollment completed in first dose cohort in imvotamab rheumatoid arthritis clinical trial - MOUNTAIN VIEW, C...
IGM Biosciences to Present at the 2024 RBCCM Global Healthcare Conference
MOUNTAIN VIEW, Calif., May 07, 2024 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company creating and developing engineered IgM antibodies, today announced ...
IGM Biosciences Announces Refocusing of Sanofi Collaboration
Agreement focuses on immunology/inflammation, aligning with Sanofi's ongoing commitment to advancing therapies for patients across multiple inflammatory diseases Agreement focuses on immunology/inflam...
IGM Biosciences to Present at the Stifel 2024 Virtual Targeted Oncology Forum
MOUNTAIN VIEW, Calif., April 10, 2024 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company creating and developing engineered IgM antibodies, today announce...
IGM Biosciences Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
MOUNTAIN VIEW, Calif., March 07, 2024 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company creating and developing engineered IgM antibodies, today announce...
IGM Biosciences: Imvotamab Data 2nd Half Of 2024 With Other Inflection Points
IGM Biosciences, Inc. is conducting phase 1b studies for imvotamab in patients with severe systemic lupus erythematosus and rheumatoid arthritis, with initial results expected in the second half of 20...
IGM Biosciences to Present at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
MOUNTAIN VIEW, Calif., Feb. 01, 2024 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company creating and developing engineered IgM antibodies, today announced...
IGM Biosciences to Present at the 42nd Annual J.P. Morgan Healthcare Conference
MOUNTAIN VIEW, Calif., Jan. 03, 2024 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company creating and developing engineered IgM antibodies, today announced...
Medivir to present at the Carlsquare Equity Research Investor Day
STOCKHOLM , Dec. 6, 2023 /PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need, annou...
IGM Biosciences Announces Strategic Pipeline Prioritization and Cash Runway Extension
– Priorities: clinical development of DR5 agonist in colorectal cancer and T cell engagers in autoimmune disease – – Plans to file IND for IGM-2644 (CD38 x CD3) to treat autoimmune disease – – All cli...
Bulletin from Extraordinary General Meeting in Medivir AB (publ)
STOCKHOLM , Dec. 1, 2023 /PRNewswire/ -- Today on 1 December 2023, Medivir AB (publ) (the "Company") held an extraordinary general meeting in Stockholm, whereby the resolution below was adopted. The ...
Medivir announces updated formulation of fostrox, critical to support planned study with accelerated approval intent in second line HCC
STOCKHOLM , Nov. 27, 2023 /PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need, anno...
Medivir to present at the Redeye Life Science Day
STOCKHOLM , Nov. 22, 2023 /PRNewswire/ -- Medivir AB (NASDAQ Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need, anno...
Medivir to present at the Erik Penser Bank Company Event
STOCKHOLM , Nov. 21, 2023 /PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need, anno...
IGM Biosciences Announces Third Quarter 2023 Financial Results
– Third IND cleared for imvotamab in autoimmune diseases – – International sites opened for aplitabart randomized clinical trial – MOUNTAIN VIEW, Calif., Nov. 13, 2023 (GLOBE NEWSWIRE) -- IGM Bioscien...
Medivir to present clinical data at ASCO-GI with fostrox + Lenvima in HCC and shares positive response from Type D meeting with FDA
STOCKHOLM , Nov. 13, 2023 /PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need, anno...
IGM Biosciences to Present at Two Upcoming Investor Conferences
MOUNTAIN VIEW, Calif., Nov. 07, 2023 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, toda...